Commentary

How to spend 2 days as a cognitive cardiologist


 

WASHINGTON – Another annual meeting of the American College of Cardiology has drawn to a close, and aside from the seemingly endless rain (and brief snow flurries), a lot of interesting discourse took place.

In the heart failure discipline, we have to a large degree become incrementalists: Although there were no blockbusters, important data on renal denervation were released, and corridor discussions about serelaxin and ivabradine were animated. At a time of ICD-10 rollouts, electronic health record (EHR) struggles, board recertification challenges, accreditation, precertification, compliance mandates, and more, it was a delight to be a cognitive cardiologist again. For a few precious moments, we could own our profession again.

©Hoard11/Thinkstockphotos.com

We saw no hospital administrators; we did not receive any missives about the (lack of) timeliness of closing encounters in EHRs; we engaged in real peer-to-peer interactions with real peers, unlike the shadow variant we deal with during an appeal of an insurance coverage decision.

And then it was over, ironically with the sun shining. It’s now back to work, but perhaps with renewed purpose. Let’s find ways to reestablish facts on the ground: Our patients and the decisions we make about our patients come first. Research and teaching do, too. Hospital administrators? Send them to a very long annual meeting. And hope that they forget to pack umbrellas.

Dr. Hauptman is professor of internal medicine and assistant dean of clinical-translational research at Saint Louis University and director of heart failure at Saint Louis University Hospital.

Recommended Reading

HFPEF’s diverse features pose management and trial challenges
MDedge Cardiology
First guidelines on pulmonary hypertension in sickle cell disease released
MDedge Cardiology
MicroRNA MIR-25 found to play key role in heart failure
MDedge Cardiology
Higher MAP target fails to improve sepsis survival
MDedge Cardiology
What’s new in non-STEMI management
MDedge Cardiology
FDA panel rejects serelaxin approval for heart failure, but urges future study
MDedge Cardiology
Survival after TAVR superior to surgery in high-risk aortic stenosis patients
MDedge Cardiology
VIDEO: Old, reliable drugs cut heart failure readmissions
MDedge Cardiology
ARB, ACE inhibitor at discharge curb heart failure readmissions
MDedge Cardiology
No improvements in left ventricular function with metformin after myocardial infarction
MDedge Cardiology